Tag Archives: metastatic pancreatic cancer

April, 2017

10 April
OncoMed’s Demcizumab Misses Primary Endpoint in Mid-Stage Pancreatic Cancer Trial

REDWOOD CITY, Calif., April 10, 2017 (GLOBE NEWSWIRE) — OncoMed Pharmaceuticals, Inc. (Nasdaq:OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer stem cell and immuno-oncology therapeutics, today reported top-line results from the company’s Phase 2 YOSEMITE clinical trial of demcizumab (anti-DLL4, OMP-21M18) in combination with Abraxane® (paclitaxel …
Share

5 August
Momenta Halts Late-Stage Pancreatic Cancer Trial After Interim Analysis

CAMBRIDGE, Mass., Aug. 04, 2016 (GLOBE NEWSWIRE) — Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the Company has discontinued further accrual in its Phase 2 trial evaluating necuparanib in combination with Abraxane® and gemcitabine in patients with advanced …
Share

22 January
Celgene Will Present Data from 10 Abraxane-Related Studies at ASCO GI Symposium

SUMMIT, NJ– (Jan. 22, 2016) – Celgene Corporation (NASDAQ: CELG) today announced that 10 studies highlighting combinations that include a foundation of ABRAXANE® (paclitaxel protein-bound particles for injectable suspension)(albumin-bound) and gemcitabine are being presented during the 2016 ASCO Gastrointestinal Cancers Symposium (ASCO GI), establishing the therapy as the foundation for …
Share